TUESDAY, SEPTEMBER 17 - WEDNESDAY, SEPTEMBER 18
DAY 1: 8:00 AM - 7:10 PM | DAY 2: 8:00 AM - 2:45 PM*
TS1: Targeting GPCRs for Drug Discovery
DAY 1: TUESDAY
8:00 am - 5:00 pm Seminar Sessions
Lunch also provided.
5:00 pm Seminar Close of Day
5:05 - 6:05 pm Interactive Breakout Discussion Groups
6:05 - 7:10 pm Welcome Reception in the Exhibit Hall with Poster Viewing
DAY 2: WEDNESDAY
8:00 - 11:20 am Seminar Sessions
11:20 am Seminar Concludes
11:20 am - 12:20 pm Lunch on Own
12:20 - 2:00 pm Plenary Keynote Program
2:00 - 2:45 pm Dessert Break in the Exhibit Hall with Poster Viewing
Exhibit Hall Refreshment Breaks also provided.
*Training Seminar times include Plenary Keynote Program, Interactive Breakout Discussions, and Exhibit Hall Refreshment Breaks.
Terry Kenakin, PhD, Professor, Department of Pharmacology, University of North Carolina School of Medicine
About This Training Seminar:
This training seminar is designed for medicinal chemists, biologists and scientists concentrating on discovering and developing drugs against G Protein-Coupled Receptors (GPCRs). The challenge the seminar addresses is how to predict therapeutic activity
– because drug candidate profiles seen in in vitro test systems often do not adequately reflect in vivo responses due to the drug candidates’ interaction with variable ambient physiology. More specifically, this seminar
describes the pharmacological procedures needed to convert ‘descriptive data’ (what we see) to ‘predictive data’ (what will be seen) through universal pharmacological scales such as affinity, efficacy, cooperativity parameters,
offset rates, etc. The desired outcome is to more fully define ligand properties to reduce attrition in late-stage drug development. Three major classes of GPCR ligands will be discussed: (1) agonists (with special reference to biased signaling),
(2) antagonists (with inverse agonists) and (3) allosteric modulators (characterization of NAMs, PAMs). I will illustrate how concepts introduced over the past 15 years have considerably expanded and revitalized the possibilities for GPCRs as therapeutic
What You Will Learn:
- How to measure the 4 Main Universal Activity Parameters for Drugs:
- What is the Affinity of the molecule for the target?
- What changes in target behavior are produced upon binding (Efficacies)?
- Is the interaction with the target orthosteric or allosteric w.r.t. endogenous ligand(s)?
- What is the rate of offset from the target (in vivo target coverage)?
- Strengths and weaknesses of functional, binding assays and kinetic assays
- Agonists: affinity vs. efficacy: Biased Agonist signaling and how to use it for drug development
- Antagonists: affinity vs. efficacy (positive or inverse agonism), non-competitive, irreversible and hemi-equilibria
- Constitutive activity: inverse agonism and its relevance
- Allosterism: binding models, parameters for characterizing agonists, antagonists, PAMs, NAMs, NAM antagonists
Terry Kenakin, PhD, Professor,
Department of Pharmacology, University of North Carolina School of Medicine
Beginning his career as a synthetic chemist, Terry Kenakin received a PhD in Pharmacology at the University of Alberta in Canada. After a postdoctoral fellowship at University College London, UK, he joined Burroughs-Wellcome as an associate scientist
(7 years). From there, he continued working in drug discovery for 25 years first at Glaxo, Inc., then GlaxoWellcome and finally as a Director at GlaxoSmithKline Research and Development laboratories at Research Triangle Park, North Carolina, USA.
Dr. Kenakin is now a professor in the Department of Pharmacology, University of North Carolina School of Medicine, Chapel Hill. Currently he is engaged in studies aimed at the optimal design of drug activity assays systems, the discovery and testing
of allosteric molecules for therapeutic application and the quantitative modeling of drug effects. In addition, he is Director of the Pharmacology graduate courses at the UNC School of Medicine. He is a member of numerous editorial boards as well
as editor in Chief of the Journal of Receptors and Signal Transduction. He has authored numerous articles and has written 10 books on Pharmacology.
RECOMMENDED PREMIUM PACKAGE:
Choose 2 Short Courses and 2 Conferences/Training Seminars
September 16 Pre-Conference Short Course: SC1: Immunology Basics: Focusing on Autoimmunity and Cancer
September 17-18 Training Seminar: TS1: Targeting GPCRs for Drug Discovery
September 18 Dinner Short Course: SC8: GPCR Structure-Based Drug Discovery
September 18-19 Conference: GPCR-Based Drug Discovery
What is a Training Seminar?
Each CHI Training Seminar offers 1.5 days of instruction with start and stop times for each day shown above and on the Event-at-a-Glance published in the onsite Program & Event Guide. Training Seminars will include morning and afternoon refreshment
breaks, as applicable, and lunch will be provided to all registered attendees on the full day of the class.
Each person registered specifically for the Training Seminar will be provided with a hard copy handbook for the seminar in which they are registered. A limited number of additional handbooks will be available for other delegates who wish to attend the
seminar, but after these have been distributed, no additional books will be available.
Though CHI encourages track hopping between conference programs, we ask that Training Seminars not be disturbed once they have begun. In the interest of maintaining the highest quality learning environment for Training Seminar attendees, and because seminars
are conducted differently than conference programming, we ask that attendees commit to attending the entire program, and not engage in track hopping, as to not disturb the hands-on style instruction being offered to the other participants.